Humanin (HN) is a recently identified endogenous peptide that protects cells against cytotoxicity induced by various stimuli. Recently, we showed that HN binds to and inhibits Bax, a pro-apoptotic Bcl-2-family protein, suggesting a mechanism for HN action. In this study, we identified Bim, a BH3-only member of the Bcl-2/Bax-family, as an additional HN 
INTRODUCTION
Humanin is a short 24-residue polypeptide, MAPRGFSCLLLLSEIDLPVKRRA, which is apparently produced at highest levels in testis, colon, AD-affected brain tissue, and some tumor cell lines (27, 28) . The mechanisms responsible for regulating levels of HN peptide in vivo are unknown, though post-translational control of HN protein stability by interactions with other proteins is among the reported possibilities (23) . Interestingly, an open reading frame corresponding to Humanin is found embedded in a ribosome gene within the mitochondrial genome, in addition to Humanin-encoding genes within the nuclear genomes of several animal species (11) , raising the possibility of gene transfer from mitochondrial to nuclear genome.
The cytoprotective mechanism of HN has been controversial. Early data suggested that HN is secreted from cells (24, 29) , and implied that a cell surface receptor is targeted by this peptide. More recently, however, our laboratory discovered an alternative mechanism of action for HN, showing that this peptide binds to Bax, and prevents the translocation of this pro-apoptotic protein from cytosol to mitochondria, thereby protecting cells from apoptosisinducing insults that trigger the mitochondrial (but not non-mitochondrial) pathway for cell death (28) . In contrast, HN does not bind multiple other Bcl-2-family members, including Bak, Bok, Bcl-2, Bcl-X L , Mcl-1, Bcl-B. Here, we extended the protective action of HN by identifying the Extra-Long isoform of Bim (BimEL) as a new target of HN. We demonstrate that the specific binding of HN to BimEL abolishes its pro-apoptotic activity by preventing BimEL-induced activation of Bax and Bak, and protecting cells from BimEL-induced cell death. Though the normal in vivo targets of Humanin remain to be clarified, these results broaden the scope of pro-apoptotic Bcl-2/Bax-family proteins that the Humanin peptide is capable of antagonizing, suggesting expanded opportunities for exploiting this anti-apoptotic peptide directly or indirectly for possible development of cytoprotective therapies.
MATERIALS AND METHODS

Cell culture and transfections. HEK293T, HeLa, MEF bax+/+, MEF bax-/-and COS-7 cells
were cultured in DMEM high-glucose medium (Irvine Scientific) containing 10% fetal bovine serum (FBS), 100 U ml -1 penicillin and 100 µg ml -1 streptomycin at 37 °C. Transfection of cells was performed using Lipofectamine PLUS reagent or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Plasmid constructions and directed mutagenesis. pEF-PGKhygro expression plasmids
incorporating the N-terminal EE (EYMPME) epitope tag and encoding BimEL, BimL and BimS have been previously described (22) . The plasmid pcDNA3-myc-Bcl-XL, incorporating a Myc epitope tag, has also been previously described (28) . A cDNA encoding human Bak was subcloned into the BamH1 and EcoR1 sites of pEGFP-C1 plasmid (Clontech). A cDNA containing the ORF of Humanin without additional flanking sequences was generated by PCR using an EST clone encoding full-length HN as a template (BE899497). The resulting PCR products were digested with restriction endonucleases and subcloned into the Xho I and Hind III sites of pEGFP-C1 (Clonthech). Site-specific mutants of Humanin were created by PCR using QuickChange Site-directed mutagenesis (Stratagene) Fmoc amino acids and resins were purchased from Nova Biochem.
In the synthesis of HN and its derivatives, Fmoc-(FmocHmb)Leu-OH is used for assembling 11 Leu, and the symmetric anhydride of Fmoc-leucine is used for adding 10 Leu to the sterically hindered (Hmb)Leu. Fmoc-Lys(Mtt) is used in addition to the above for the synthesis of FITC-HN.
The peptides were deprotected and cleaved from the resin by treatment with 
Bax activation assays.
To examine conformational changes in Bax associated with activation of this protein, mitochondria (100 µg) were lysed in fractionation buffer supplemented with 1% CHAPS and subjected to immunoprecipitation with anti-Bax 6A7 monoclonal antibody (Sigma). Then, the resulting immune-complexes were analyzed by immunoblotting using polyclonal Bax (N-20) antibody (Santa Cruz Biotechnology).
Smac antibody production. Polyclonal antisera recognizing SMAC were generated in New
Zealand rabbits using peptide (AR-49) or recombinant protein (AR-50A; B) immunogens.
SMAC recombinant protein was produced as a GST-fusion protein and affinity-purified as described previously (31) .The SMAC anti-peptide antibody (AR-49) was generated using a synthetic peptide (NH2 -AVPLAQKSEPHSLSSEALC -amide) corresponding to residues 55-73 of human (hu) SMAC, which was synthesized with an N-terminal cysteine appended to permit conjugation to maleimide-activated carrier proteins KLH and OVA (Pierce, Inc.) (32) .
The mono-specificity of all antibodies for their intended protein targets was confirmed by SDS-PAGE/immunoblot analysis.
RESULTS
Humanin binds to BimEL. We previously showed that HN can bind the pro-apoptotic protein Bax but not several other anti-apoptotic Bcl-2-family members (28) We then compared BimEL with the two other Bim isoforms, BimL and BimS, generated by alternative splicing (Fig.1C ). For these experiments, we co-expressed the three isoforms of Bim, BimEL, BimL and BimS as EE-tagged proteins along, with GFP-HN in HEK293T cells by co-transfection.
With these cell lysates, we preformed immunoprecipitations using monoclonal anti-EE antibody and analyzed the resulting immunecomplexes using anti-GFP antibody to detect associated GFP-HN ( Figure 1D ). While We also compared the effects of GFP-HN on caspase activation induced by BimEL, BimL, and BimS, to determine whether binding to GFP-HN correlates with suppression of apoptosis. As shown in Figure 3B , all three Bim isoforms induced similar fold-increases in caspase activity in transfected HEK293T cells. However, GFP-HN only suppressed caspase activation induced by BimEL but not by BimL or BimS ( Figure 3B ). We conclude therefore that the ability of HN to suppress Bim-induced caspase activation correlates with binding to
Bim protein, such that only the isoform of Bim that binds HN is suppressed.
To confirm the specificity of these results, we performed complementary experiments in which a mutant version of HN lacking cytoprotective activity was tested for binding to BimEL. In this regard, substitution of proline for cysteine at position 8 of the HN peptide has been shown to abrogate its ability to rescue neuronal cells from apoptosis (24, 26) . Moreover, we previously showed that Cys8Pro (C8P) mutant HN fails to bind Bax and is unable to protect cells against Bax-induced cell death (28) . We therefore compared the ability of wild- To confirm the specificity of these results obtained with wild-type HN peptide, we compared the effects of mutant HN(Cys8Pro) peptide, using isolated mitochondria. In contrast to wild-type HN peptide, mutant HN(Cys8Pro) peptide did not block BimEL-induced
Smac release even at 50 µM ( Figure 7A) . In addition, we tested the ability of HN peptide to block mitochondrial release of Smac induced by an alternative stimulus predicted to be resistant to HN. Namely, we used a BH3 peptide of Bak, which is known to induce Cytochrome c release from isolated mitochondria (35) , presumably by displacing antiapoptotic Bcl-2-family proteins from mitochondria-resident pro-apoptotic proteins. In contrast to BimEL, Smac release induced by Bak BH3 peptide was not significantly blocked by HN peptide ( Figure 7B ). Taken together, these results confirm the specificity of HN-based suppression of BimEL-induced release of apoptogenic proteins from isolated mitochondria.
Note that the synthetic HN peptide used here is the same as the peptide used for cell culture experiments above thus confirming that this non-Arg 8 tagged peptide is an active inhibitor of BimEL in vitro though it cannot penetrate cell membranes.
Humanin peptide prevents BimEL-induced Bax activation. We performed additional experiments to explore the mechanism by which HN interferes with the pro-apoptotic action of BimEL. BimEL is one of the few BOPs that can operate as either an antagonist of antiapoptotic or as an agonist of pro-apoptotic Bcl-2/Bax-family proteins (36) . With respect to antagonism of anti-apoptotic Bcl-2/Bax-family proteins, we examined the effects of HN on association of BimEL with anti-apoptotic proteins Bcl-2 and Mcl-1 by coimmunoprecipitation experiments, but observed no effect (data not shown). Thus, HN is unlikely to interfere with the ability of BimEL to antagonize anti-apoptotic members of the Bcl-2 family.
We therefore turned our attention to an analysis of the effects of HN on pro-apoptotic protein Bax, asking whether HN interferes with the ability of BimEL to induce activation of Figure 10A ). To control for specificity, we repeated these Bak oligomerization assays using HN (Cys8Pro) control peptide. Unlike wild-type HN, which inhibited Bax olgomerization at concentrations as low as 3-10 µM, the HN (Cys8Pro)
peptide was inactive at concentrations as high as 50 µM ( Figure 10B ).
Structure-function analysis of HN peptide interaction with BimEL. Our previous data
showed that the first 1-17 amino acid of HN is required for binding to Bax (28) . To begin to delineate some of the structure-function relations of the HN peptide with respect to BimEL binding and suppression, we compared the effects of fragments of the HN peptide representing either the first or the last 12 amino-acids of this peptide (e.g, 1-12 and 13-24).
To determine whether either the N-or C-terminal half of HN can bind BimEL, we expressed these segments of HN as GFP fusion proteins in HEK293T cells along with EE-tagged BimEL, and performed co-immunoprecipitation experiments, making comparisons with fulllength HN protein. Immunoprecipitation of BimEL using anti-Bim antibody revealed the presence of associated GFP-HN and GFP-HN(1-12) but not GFP-HN (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Immunoblot analysis of the lysates confirmed production of the GFP-HN(1-12) and GFP-HN (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) proteins at comparable levels, thus excluding differences in the levels of these fusion proteins as a trivial explanation for the differential binding to BimEL ( Figure 11A ).
Next, we tested the effects of synthetic HN(1-12) and HN(13-24) peptides on BimELinduced release of SMAC from isolated mitochondria ( Figure 11B ). Whereas HN (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) peptide suppressed in a concentration-dependent manner the amount of SMAC released from mitochondria following treatment with recombinant BimEL protein, HN(13-24) did not.
Finally, the ability of GFP-HN(1-12) to suppress apoptosis induced by expression of BimEL was tested, using caspase activity as a surrogate for apoptosis. In transfected HEK293T cells, BimEL-induced an increase in caspase activity, which was significantly suppressed by co-expression of GFP-HN or GFP-HN(1-12) but not GFP-HN(13-24) ( Figure   11C ).
We conclude therefore that the first 12 amino-acids of the HN peptide are necessary and sufficient to bind BimEL and to suppress BimEL activity in vitro and in cells.
DISCUSSION
Previously, we reported a new mechanism of action for the endogenous cytoprotective peptide HN, showing that it binds and inhibits pro-apoptotic protein Bax (28) . In this study, we extended the protective action of HN by identifying the Extra-Long isoform of Bim His 6 -BimEL (300 ng) was preincubated with or without 50 µM of HN peptide for 10 min, then 50 µg of isolated mitochondria was added. After incubation at 30°C for 1 hr, samples were centrifuged and the resulting mitochondria-containing pellets and supernatants were analyzed by SDS-PAGE /immunoblotting using Smac, Bax, and Hsp60 polyclonal antibodies.
To examine Bax conformational change, mitochondrial pellets were lysed in 1%
CHAPS and subjected to immunoprecipitation with anti-Bax 6A7 monoclonal antibody. IPs were analyzed by SDS-PAGE/immunoblotting using polyclonal anti-Bax antibody (bottom panel). 
